Given its critical role in neuronal survival and disease, TrkA has become a therapeutic target. NGF mimetics and TrkA agonists are being developed to treat neurodegenerative diseases by enhancing TrkA signaling. Conversely, TrkA inhibitors are being explored for the treatment of cancers where TrkA is aberrantly activated.